De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

NeuBase Therapeutics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Todd Branning

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.3yrs
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	3.5yrs

Recente managementupdates

Recent updates

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

May 12

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Jan 24

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Oct 02

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Jun 02

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Feb 23

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

Jan 19

NeuBase Therapeutics EPS in-line

Dec 23

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Dec 16

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

Dec 15

Analyse CEO-vergoeding

Hoe is Todd Branning's beloning veranderd ten opzichte van NeuBase Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2023	n/a	n/a	-US$25m
Dec 31 2022	n/a	n/a	-US$30m
Sep 30 2022	US$922k	US$311k	-US$34m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Todd redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Todd te vergelijken met de prestaties van het bedrijf.

CEO

Todd Branning (53 yo)

2.3yrs

Tenure

US$922,445

Compensatie

Mr. Todd P. Branning serves as an Interim Chief Executive Officer since January 16, 2024 and Chief Financial Officer of NeuBase Therapeutics, Inc. since January 2022 and serves as its Secretary. He joined...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Dietrich Stephan	Founder	4.8yrs	US$1.15m	6.14% $ 87.1k
Dov Goldstein	Independent Chairperson	4.8yrs	US$74.42k	0.040% $ 567.0
Eric Richman	Independent Director	4.8yrs	US$68.38k	0.060% $ 849.3
George Church	Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Steven Dowdy	Member of Gene Editing & Scientific Advisory Board	4.6yrs	geen gegevens	geen gegevens
James Coull	Member of Gene Editing Advisory Board	less than a year	geen gegevens	geen gegevens
Randy Davis	Member of Scientific Advisory Board	3.5yrs	geen gegevens	geen gegevens
Danith Ly	Member of Advisory Board	no data	geen gegevens	geen gegevens
Robert Friedlander	Chair of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Peter Nielsen	Member of Gene Editing & Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
Eriks Rozners	Member of Gene Editing & Scientific Advisory Board	3.5yrs	geen gegevens	geen gegevens
Gerald Mcdougall	Independent Director	3yrs	US$59.79k	0% $ 0

3.5yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NBSE wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

NeuBase Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

NeuBase Therapeutics, Inc. Announces CEO Changes

Neubase Therapeutics, Inc. Announces Franklyn G. Prendergast Board of Directors Passed Away

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 28, 2023

High number of new and inexperienced directors

NeuBase Therapeutics, Inc. Announces Resignation of Eric J. Ende as Board of Director

NeuBase Therapeutics, Inc. Announces Formation of Gene Editing Advisory Board

Recent updates

NeuBase Therapeutics Files Form 15

NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from S&P TMI Index

New major risk - Financial data availability

The Nasdaq Stock Market LLC Notifies NeuBase Therapeutics Regarding Non-Compliance with the Minimum Bid Price Requirement and Ineligible for a Second 180 Calendar Day Period to Regain Compliance

NeuBase Therapeutics, Inc. Announces CEO Changes

New minor risk - Financial data availability

NeuBase Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Neubase Therapeutics, Inc. Announces Franklyn G. Prendergast Board of Directors Passed Away

New major risk - Shareholder dilution

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 28, 2023

High number of new and inexperienced directors

NeuBase Therapeutics, Inc. announced that it has received $3.512751 million in funding

NeuBase Therapeutics, Inc. Presents Non-Human Primate Data Illustrating Stealth Editors Are Non-Immunogenic, Opening the Door to Redosing

Neubase Therapeutics, Inc. Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors

NeuBase Therapeutics, Inc. Announces Resignation of Eric J. Ende as Board of Director

NeuBase Therapeutics, Inc. Announces Formation of Gene Editing Advisory Board

Price target decreased to US$10.00

NeuBase Therapeutics, Inc. Announces Resignation of William Mann as President and Chief Operating Officer, Effective October 31, 2022

NeuBase Therapeutics, Inc. to Reduces its Workforce by Approximately 60%

NeuBase Therapeutics, Inc. Announces Executive Changes

Price target decreased to US$10.67

NeuBase Therapeutics Receives Non-Compliance Letter from Nasdaq

Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 08, 2022

NeuBase Therapeutics, Inc. Announces Promotion of William Mann to President

NeuBase Therapeutics promotes Dr. William Mann to President and COO

NeuBase Therapeutics, Inc. Presents New Preclinical Data At ASGCT 2022 for Its Dm1 Program Demonstrating Wide Tissue Distribution and Supporting Differentiated Whole-Body Treatment Solution

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

Price target decreased to US$14.67

High number of new and inexperienced directors

Price target decreased to US$14.67

Price target decreased to US$15.50

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

CFO, Treasurer & Secretary Samuel Backenroth has left the company

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from Russell 3000E Index

NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Independent Director has left the company

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Price target raised to US$17.00

New 90-day high: US$11.66

New 90-day high: US$10.08

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

New 90-day low: US$7.27

NeuBase Therapeutics EPS in-line

NeuBase Therapeutics Announces Positive Preclinical in Vivo Data for Patrol Enabled Anti-Gene for the Treatment of Myotonic Dystrophy Type 1

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

NeuBase Therapeutics Announces Appointment of Curt Bradshaw as Chief Scientific Officer

NeuBase Therapeutics Announces Addition of Eriks Rozners and Randy Davis to Scientific Advisory Board

NeuBase Therapeutics, Inc. Announces Addition of Peter Nielsen, Ph.D., Inventor of Peptide Nucleic Acid Technology, to Scientific Advisory Board

NeuBase Therapeutics, Inc. Enters into Lease Agreement with 350 Technology Drive Partners, LLC

New 90-day low - US$7.46

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd